WO2002060869A3 - Use of p38 inhibitors for the treatment of inflammation-enhanced cough - Google Patents

Use of p38 inhibitors for the treatment of inflammation-enhanced cough Download PDF

Info

Publication number
WO2002060869A3
WO2002060869A3 PCT/US2001/050629 US0150629W WO02060869A3 WO 2002060869 A3 WO2002060869 A3 WO 2002060869A3 US 0150629 W US0150629 W US 0150629W WO 02060869 A3 WO02060869 A3 WO 02060869A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
inflammation
inhibitors
enhanced cough
cough
Prior art date
Application number
PCT/US2001/050629
Other languages
French (fr)
Other versions
WO2002060869A2 (en
Inventor
Don E Griswold
David C Underwood
Original Assignee
Smithkline Beecham Corp
Don E Griswold
David C Underwood
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Don E Griswold, David C Underwood filed Critical Smithkline Beecham Corp
Priority to US10/399,579 priority Critical patent/US20040097473A1/en
Priority to EP01997150A priority patent/EP1337255A4/en
Priority to AU2002248269A priority patent/AU2002248269A1/en
Priority to JP2002561020A priority patent/JP2004530648A/en
Publication of WO2002060869A2 publication Critical patent/WO2002060869A2/en
Publication of WO2002060869A3 publication Critical patent/WO2002060869A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

The present invention is directed to the novel use of a CSBP/p38 inhibitor for the treatment, including prophylaxis of inflammation enhanced cough in a mammal in need thereof.
PCT/US2001/050629 2000-10-19 2001-10-19 Use of p38 inhibitors for the treatment of inflammation-enhanced cough WO2002060869A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/399,579 US20040097473A1 (en) 2001-10-19 2001-10-19 Use of p38 inhibitors for the treatment of smoke inhalation
EP01997150A EP1337255A4 (en) 2000-10-19 2001-10-19 Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU2002248269A AU2002248269A1 (en) 2000-10-19 2001-10-19 Use of p38 inhibitors for the treatment of inflammation-enhanced cough
JP2002561020A JP2004530648A (en) 2000-10-19 2001-10-19 Use of p38 inhibitors for the treatment of inflammation-promoted cough

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24156400P 2000-10-19 2000-10-19
US60/241,564 2000-10-19

Publications (2)

Publication Number Publication Date
WO2002060869A2 WO2002060869A2 (en) 2002-08-08
WO2002060869A3 true WO2002060869A3 (en) 2003-01-03

Family

ID=22911205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/050629 WO2002060869A2 (en) 2000-10-19 2001-10-19 Use of p38 inhibitors for the treatment of inflammation-enhanced cough

Country Status (4)

Country Link
EP (1) EP1337255A4 (en)
JP (1) JP2004530648A (en)
AU (1) AU2002248269A1 (en)
WO (1) WO2002060869A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940756B2 (en) 2012-06-07 2015-01-27 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CZ20031125A3 (en) 2000-10-23 2003-10-15 Smithkline Beecham Corporation Novel compounds
PL373339A1 (en) 2002-04-19 2005-08-22 Smithkline Beecham Corporation Novel compounds
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
EP1868612A4 (en) 2005-03-25 2010-03-24 Glaxo Group Ltd Novel compounds
PE20061193A1 (en) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVATIVES OF 3,4-DIHYDROPYRIMIDO [4,5-d] PYRIMIDIN-2- [1H] -0NA AS KINASE INHIBITORS p38
MX2007012951A (en) 2005-03-25 2008-01-11 Glaxo Group Ltd Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives.
UY29440A1 (en) 2005-03-25 2006-10-02 Glaxo Group Ltd NEW COMPOUNDS
WO2006137421A1 (en) * 2005-06-21 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. Agent for topical administration
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
CN114732910A (en) 2017-10-05 2022-07-12 弗尔康医疗公司 P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
KR20220045189A (en) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. How to treat gastrointestinal stromal tumors
TW202122082A (en) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 Methods of treating gastrointestinal stromal tumors
BR112022013169A2 (en) 2019-12-30 2022-09-13 Deciphera Pharmaceuticals Llc COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAFTIRIDIN-3-YL)-2-FLUOROFEYL)-3- PHENYLUREA
MX2022008103A (en) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Amorphous kinase inhibitor formulations and methods of use thereof.
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
WO1997025046A1 (en) * 1996-01-11 1997-07-17 Smithkline Beecham Corporation Novel substituted imidazole compounds
US5716972A (en) * 1993-01-13 1998-02-10 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1017378T3 (en) * 1997-09-23 2003-03-17 Astrazeneca Ab Amide derivatives to treat diseases mediated by cytokines
PL363116A1 (en) * 1999-09-17 2004-11-15 Smithkline Beecham Corporation Use of csaids in rhinovirus infection
ES2249309T3 (en) * 1999-11-23 2006-04-01 Smithkline Beecham Corp COMPOUNDS OF 3,4-DIHIDRO- (1H) QUINAZOLIN-2-ONA AS INHIBITORS OF CSBP / P39 KINASA.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716972A (en) * 1993-01-13 1998-02-10 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
WO1997025046A1 (en) * 1996-01-11 1997-07-17 Smithkline Beecham Corporation Novel substituted imidazole compounds
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1337255A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940756B2 (en) 2012-06-07 2015-01-27 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases

Also Published As

Publication number Publication date
EP1337255A4 (en) 2006-01-25
JP2004530648A (en) 2004-10-07
EP1337255A2 (en) 2003-08-27
WO2002060869A2 (en) 2002-08-08
AU2002248269A1 (en) 2002-08-12

Similar Documents

Publication Publication Date Title
WO2002060869A3 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
YU5503A (en) Non-steroidal inflammation inhibitors
WO2002003995A3 (en) Treatment of male sexual dysfunction
EP1862457A3 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2003002553A3 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
AU2002316437A1 (en) Pyrrolidines as dipeptidyl peptidase inhibitors
PL362546A1 (en) Benzamide compounds as apo b secretion inhibitors
MXPA02011411A (en) Serine protease inhibitors.
EP1307203A4 (en) Protease inhibitors
HUP0101616A3 (en) Substituted benzamides, their production and their use as cysteine protease inhibitors
ATE332129T1 (en) TREATING ACNE WITH LIPOXYGENASE INHIBITORS
IS6759A (en) New thiadiazole and oxadiazole and their use as phosphodiesterase-7 inhibitors
MY138732A (en) Conjugated complement cascade inhibitors
MXPA03005254A (en) Serine protease inhibitors.
PL370766A1 (en) Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
GB0030303D0 (en) Compounds
GB0011358D0 (en) Novel use
GB0030306D0 (en) Compounds
WO2003076391A3 (en) Urokinase inhibitors, production and use thereof
IL153421A0 (en) Protease inhibitors
PL359263A1 (en) Novel mmp-2/mmp-9 inhibitors
WO2002032862A3 (en) Use of p38 inhibitors for the treatment of smoke inhalation
WO2001074348A8 (en) Vasopeptidase inhibitors to treat isolated systolic hypertension
HK1053785A1 (en) Protease inhibitors
AU1142502A (en) Novel crystalline forms of a factor xa inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002561020

Country of ref document: JP

Ref document number: 10399579

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001997150

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001997150

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001997150

Country of ref document: EP